

Product Datasheet

LEE011

Catalog No. **BP-02301** · CAS **1211441-98-3** · Form **free base** · Physical state **solid** · Color **Off-white to yellow** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target CDK	Research area Neurological Disease; Cancer
----------------------	--

Molecular formula **C₂₃H₃₀N₈O**

Molecular weight **434.5373**

STRUCTURE



DESCRIPTION

Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

BIOLOGICAL ACTIVITY

In Vitro

Ribociclib (500 nM; 6 days) inhibits the growth of neuroblastoma cell lines BE2C and IMR5.

In Vivo

Ribociclib (200 mg/kg; p.o.; 21 days) delays tumor growth in CB17-immunodeficient BE2C or 1643 xenograft mice.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.

[2]. Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.